Delivery Order 75N93021D00002-75N93021F00002
Award Date
4/15/21
Potential Completion Date
8/14/21
Potential Value
$17K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Alchem Laboratories Corporation
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Alachua, FL 32615, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This task order funds the guaranteed minimum amount under the Preclinical Services for HIV Therapeutics contract vehicle with the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The $0 potential value indicates the order is funding pre-established contract capacity rather than discrete services. Alchem Laboratories Corporation will perform the preclinical services as the prime contractor, with place of performance in Alachua, Florida. No set-aside...
This is a $2,332,902 cost-plus-fixed-fee delivery order awarded by the National Cancer Institute (NCI) to Alchem Laboratories Corporation, a for-profit manufacturer based in Florida. The contract is for the synthesis of non-GMP (non-Good Manufacturing Practice) small molecule samples to support the NCI's research. Alchem Laboratories has multiple federal indefinite delivery vehicle (IDV) contracts with the NCI and National Institute of Allergy and Infectious Diseases (NIAID) for preclinical...
This is a $5,623,209.67 cost-plus-award-fee contract awarded by the National Cancer Institute to Alchem Laboratories Corporation, a for-profit pharmaceutical manufacturer in Alachua, Florida. The contract is for the synthesis of non-GMP small molecule samples to support the National Cancer Institute's research. It has an ultimate completion date of September 30, 2012. Alchem Laboratories is also an awardee on several indefinite delivery vehicle (IDV) contracts with the National Cancer...
This is a $3,171,368.00 cost-plus-fixed-fee delivery order awarded to Alchem Laboratories Corporation, a for-profit manufacturer of pharmaceutical products, by the National Cancer Institute (NCI), a civilian agency. The contract is for the synthesis of up to ten non-GMP (non-Good Manufacturing Practice) small molecule samples per year, as continuity for the NCI's Program 66C, through September 2026. Alchem Laboratories holds multiple federal indefinite delivery vehicle (IDV) contracts for...
This is a $6,101,176.11 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute (NCI) to Alchem Laboratories Corporation, a small business manufacturer, for the non-GMP synthesis of compounds to support drug development. The contract has a period of performance through September 2021. Alchem Laboratories Corporation is a custom research organization that performs specialized services including custom organic synthesis, current Good Manufacturing Practice (cGMP)...
This is a definitive federal contract awarded by the National Cancer Institute (NCI), a civilian agency, to Alchem Laboratories Corporation, a for-profit manufacturer of pharmaceutical ingredients. The $2,860,070.26 cost-plus-fixed-fee contract is for the manufacture of bulk chemicals and pharmaceutical ingredients to support preclinical and clinical studies. The contract has a completion date of June 4, 2022 and was set aside for small businesses. Alchem Laboratories is the prime contractor and...
This cost-plus-fixed-fee delivery order, valued at one million three hundred ninety-three thousand seven hundred twenty-two dollars ($1,393,722), was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. of Potomac, Maryland. The order is placed against the HIV Microbicides and Biomedical Prevention 2016-2021 master IDIQ contract to perform quality evaluation and documentation of study products to certify...
Advanced Bioscience Laboratories, Inc., doing business as Advanced Bioscience Laboratories Inc., has been awarded an $893,336 cost-plus-fixed-fee delivery order against the HIV Microbicides and Biomedical Prevention 2016-2021 master indefinite-delivery/indefinite-quantity contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases. Under this award, the contractor will provide expertise in the development and optimization of antiretroviral therapy for...
This delivery order was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to the University of Nebraska Medical Center under the Preclinical Services for HIV Therapeutics master IDIQ contract. The $13,328.86 order is for the development and delivery of a quality assurance/quality control plan and participation in a task order initiation meeting to support the NIH's work in HIV/AIDS therapeutics research. Performance will take place in Omaha,...
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. (ABL), a contract research and manufacturing organization. The $3,150,428.64 award is a delivery order under the HIV Microbicides and Biomedical Prevention 2016-2021 indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. ABL will provide comprehensive resources for HIV...